1. Rhodobacter azotoformans LPS (RAP99-LPS) Is a TLR4 Agonist That Inhibits Lung Metastasis and Enhances TLR3-Mediated Chemokine Expression.
- Author
-
Murakami K, Kamimura D, Hasebe R, Uchida M, Abe N, Yamamoto R, Jiang JJ, Hidaka Y, Nakanishi Y, Fujita S, Toda Y, Toda N, Tanaka H, Akira S, Tanaka Y, and Murakami M
- Subjects
- Animals, Male, Mice, Mice, Inbred C3H, Mice, Inbred C57BL, NF-kappa B physiology, STAT3 Transcription Factor physiology, Chemokines genetics, Lipopolysaccharides pharmacology, Lung Neoplasms prevention & control, Lung Neoplasms secondary, Rhodobacter chemistry, Toll-Like Receptor 3 physiology, Toll-Like Receptor 4 agonists
- Abstract
The lipopolysaccharides (LPSs) of Rhodobacter are reported to be TLR4 antagonists. Accordingly, the extract of Rhodobacter azotoformans (RAP99) is used as a health supplement for humans and animals in Japan to regulate immune responses in vivo . We previously analyzed the LPS structure of RAP99 (RAP99-LPS) and found it is different from that of E. coli -LPS but similar to lipid A from Rhodobacter sphaeroides (RSLA), a known antagonist of TLR4, with both having three C14 fatty acyl groups, two C10 fatty acyl groups, and two phosphates. Here we show that RAP99-LPS has an immune stimulatory activity and acts as a TLR4 agonist. Pretreatment of RAP99-LPS suppressed E. coli -LPS-mediated weight loss, suggesting it is an antagonist against E. coli -LPS like other LPS isolated from Rhodobacter . However, injections of RAP99-LPS caused splenomegaly and increased immune cell numbers in C57BL/6 mice but not in C3H/HeJ mice, suggesting that RAP99-LPS stimulates immune cells via TLR4. Consistently, RAP99-LPS suppressed the lung metastasis of B16F1 tumor cells and enhanced the expression of TLR3-mediated chemokines. These results suggest that RAP99-LPS is a TLR4 agonist that enhances the activation status of the immune system to promote anti-viral and anti-tumor activity in vivo ., Competing Interests: YH, YN, SF, YT and NT were employed by TFK Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Murakami, Kamimura, Hasebe, Uchida, Abe, Yamamoto, Jiang, Hidaka, Nakanishi, Fujita, Toda, Toda, Tanaka, Akira, Tanaka and Murakami.)
- Published
- 2021
- Full Text
- View/download PDF